



Efficacy of *N*-acetylcysteine and all-*trans* retinoic acid in restoring in vitro effective hemopoiesis in myelodysplastic syndromes

Agostino Cortelezzi ^{a,*}, Chiara Cattaneo ^a, Barbara Sarina ^a, Silvia Cristiani ^a,
Mauro Pomati ^a, Ilaria Silvestris ^a, Marina Motta ^a, Adalberto Ibatici ^a,
Gianluca Gornati ^b, Aldo Della Volpe ^c, Anna Teresa Maiolo ^a

^a Servizio Autonomo di Ematologia Diagnostica, Ospedale Maggiore Policlinico IRCCS, Via F. Sforza 35, 20122 Milan, Italy

^b Centro Trasfusionale, Istituti Clinici di Perfezionamento, Milan, Italy

^c Centro Trapianti di Midollo, Ospedale Maggiore Policlinico IRCCS, Milan, Italy

Received 26 April 1999; accepted 20 August 1999

Abstract

We evaluated the in vitro effect on clonogenic potential (CFU-GM) and apoptosis in myelodysplastic syndromes (MDS) progenitors of an anti-oxidant (*N*-acetylcysteine, NAC) and/or a differentiating (all-*trans* retinoic acid, ATRA) agent. NAC significantly reduced apoptosis, both NAC and ATRA induced an increase in CFU-GM, but NAC seemed to be particularly effective in the high risk (HR) MDS. NAC + ATRA conferred a significant advantage in terms of CFU-GM with respect to NAC and ATRA alone. Tumor Necrosis Factor- α (TNF- α) levels decreased after incubation with NAC in the MDS samples. This study shows that ineffective hemopoiesis in MDS could benefit from both NAC and ATRA, suggesting that anti-oxidant treatment may play a role in guaranteeing MDS cell survival, predisposing them towards differentiation. © 2000 Published by Elsevier Science Ltd. All rights reserved.

Keywords: Myelodysplastic syndromes; *N*-acetylcysteine; All-*trans* retinoic acid; Apoptosis; Clonogenic activity

1. Introduction

Increased bone marrow apoptosis and ineffective hemopoiesis are the two main characteristics of the myelodysplastic syndromes (MDS) [1–6]. The former, which is at least partially responsible for premature intramedullary cell death, is particularly pronounced in low-risk MDS (such as refractory anemia, RA and refractory anemia with ring sideroblasts, RARS), whereas the latter leads to the well known maturation arrest of bone marrow (BM) progenitors, but both

determine the often severe and life-threatening cytopenia(s) typical of MDS.

It is well documented that MDS patients have increased serum Tumor Necrosis Factor- α (TNF- α) levels [7–11], which may be responsible for pro-apoptotic oxidative damage by inducing the generation of free radicals [12–16]. In line with this hypothesis, Peddie et al. [17] have demonstrated the presence of oxidative damage and a reduction in intracellular glutathione (GSH) in MDS CD34+ cells, and a number of in vitro studies have shown the ability of the antioxidant thiol *N*-acetylcysteine (NAC) to reduce the apoptosis induced by free radicals in neuronal and leukemic cell lines by increasing the supply of intracellular GSH [18–20]. NAC also acts as an antiapoptotic agent by inhibiting TNF- α release from lymphocytes and accessory cells [21].

MDS bone marrow (BM) progenitors can be induced to differentiate and mature in vitro by using various differentiating agents, such as vitamin D₃ and E, Ara-

Abbreviations: ATRA, all-*trans*-retinoic acid; BM, bone marrow; BMMNC, bone marrow mononuclear cell; HR, high risk; LR, low risk; MDS, myelodysplastic syndromes; NAC, *N*-acetylcysteine; RA, refractory anemia; RAEB, refractory anemia with excess of blasts; RAEB-t, refractory anemia with excess of blasts in transformation; RARS, refractory anemia with ring sideroblasts; TNF- α , tumor necrosis factor- α .

* Corresponding author. Tel.: +39-02-5503-3429/3345; fax: +39-02-5503-3380.

E-mail address: cortelez@polic.cilea.it (A. Cortelezzi)

C, butyrates and amifostine and this has provided the rationale for several clinical trials [22].

ATRA is a natural metabolite of retinol, whose differentiating activity has also been demonstrated in non-APL blast cells [23]. However, when used in vivo, the ability of ATRA alone to restore defective hemopoiesis in MDS has not always been demonstrated [24–30].

On the basis of these observations we incubated MDS progenitor cells in vitro first with NAC alone and after 24 h with ATRA alone or in combination in order to explore their activity in terms of enhanced clonogenic potential (CFU-GM), reduced apoptosis and stimulated differentiation. The rationale of the sequence (first NAC then ATRA) was based on the hypothesis of first reducing the degree of apoptosis by means of an antioxidant, and then stimulating differentiation via ATRA. The possible role of TNF- α in inducing free radicals was evaluated by determining TNF- α levels in bone marrow plasma and in supernatants of liquid cultures.

2. Patients

The BM cells were obtained from 25 patients with de novo MDS (21 males and 4 females, with a median age of 68 years: range 34–86) and seven normal bone marrow donors, after they had given their informed consent. On the basis of the FAB criteria, the patients were classified as being affected by RA ($n = 6$), RARS ($n = 7$), RAEB ($n = 10$) and RAEB-t ($n = 2$). For the purpose of the study, we classified RA + RARS as low risk (LR) MDS and RAEB + RAEB-t as high risk (HR) MDS.

3. Methods

3.1. Cell preparation

The BM samples were collected in preservative-free heparin. The mononuclear cells (MNCs) were separated by means of gradient centrifugation using Ficoll Lymphoprep (Nicomed Pharma Oslo, Norway), evaluated for apoptosis and then suspended in IMDM (Gibco Europe, Paisley, UK) with 10% FCS (Hyclone, Logan, Utah, USA) at a concentration of 1×10^6 /ml and incubated at 37°C in 5% CO₂ ± NAC 0.5 mM for 24 h. After this time, some of the cells ± NAC (Sigma, Saint Louis, MO, USA) were evaluated for CFU-GM and apoptosis and others were cultured ± ATRA 5 μ M (kindly provided by Roche) for a further 24 h. After a total culture time of 48 h, the cells incubated with ATRA, NAC, NAC + ATRA as well as the control

Due to the scanty cell recovery from MDS BM, the samples incubated for 48 h with NAC alone were evaluated in only 12/25 cases. The viability after liquid incubation was always > 90% evaluated by the Trypan blue exclusion test.

3.2. Apoptosis

Apoptosis was evaluated by means of a TdT/dUTP assay using the commercially available 'In Situ Cell Death Fluorescein Detection Kit' (Boehringer Mannheim, Germany). Briefly, $1-2 \times 10^6$ cells were fixed in cold ethanol 70% in PBS, and stored at 4°C until use. Before staining, the cells were washed in PBS, permeabilized with 100 μ l TritonX-100 0.1% in sodium citrate 0.1% for 2 min on ice, and again washed twice in PBS. After incubation for 1 h at 37°C with dUTP FITC, with and without TdT, samples were again washed in PBS, resuspended in 500 μ l of PBS and made ready for cytofluorimetric analysis. A total of 1×10^4 events were analyzed.

3.3. CFU-GM

A volume of 1×10^5 cells/ml in IMDM were cultured in 1 ml of a mixture containing 20% FCS, 0.3% agar, GM-CSF 200 U/ml, IL-3 100 U/ml and SCF 8 U/ml (Genzyme Cambridge, MA, USA) and the plates were incubated in humidified air with 5% CO₂ at 37°C for 14 days. The aggregates containing > 50 cells were scored as colonies, whereas those containing < 50 cells were scored as clusters. All of the cultures were set up in quadruplicate. In order to exclude interference due to the absence of reducing equivalents in the agar assay, clonogenic tests using methylcellulose (HF 4434, Stem Cell Technologies Vancouver, Canada) were also made in a subset of patients.

3.4. TNF- α levels in BM plasma and liquid culture

The plasma samples obtained by spinning the BM samples at 3000 rpm were stored at -20°C until used, and then investigated for their TNF- α content by means of a commercially available immunoenzymatic-assay kit (Medgenix Diagnostic, Fleurus, Belgium). The TNF- α levels in the supernatants of 24 h liquid cultures were also evaluated. The minimum detectable dose of TNF- α was 3.0 pg/ml.

3.5. Statistical analysis

The Wilcoxon matched pairs signed ranks test was used to evaluate within-group differences, and the Mann-Whitney test for differences between groups. A *P* value of < 0.05 was considered to be statistically

4. Results

4.1. Evaluation of apoptosis in fresh bone marrow mononuclear cells (BMMNCs)

The apoptosis evaluated in fresh MDS BMMNCs was higher than that observed in the normal samples (1.67 ± 0.16 SE versus 1.49 ± 0.27 , n.s.). Apoptosis was even higher in the LR group (LR: 2.02 ± 0.22 , $P < 0.05$ versus normals).

4.2. Evaluation of apoptosis after 24 h of incubation with NAC

In the normal samples, apoptosis was significantly ($P < 0.05$) less after NAC incubation in comparison with controls (3.03 ± 0.74 versus 4.1 ± 0.84). It was also less after NAC stimulation in the MDS samples as a whole (2.12 ± 0.52 versus 3.44 ± 0.66) ($P < 0.01$), as well as in the two subgroups (LR: 2.06 ± 0.68 versus 3.67 ± 0.93 ; HR: 2.18 ± 0.83 versus 3.16 ± 0.96) ($P < 0.05$ and $P < 0.01$, respectively) (Fig. 1).

4.3. Clonogenic assay (CFU-GM) after 24 h of incubation with NAC

The number of CFU-GM was significantly higher in the NAC treated normal than in the controls (195.6 ± 49.72 versus 153.8 ± 45.98) ($P < 0.05$). A significant increase in the number of CFU-GM was also observed in the MDS patients after NAC incubation (MDS: 73.39 ± 12.88 versus 57.3 ± 11.24 , $P < 0.01$; LR: 78.69 ± 14.59 versus 61.85 ± 13.79 , $P < 0.01$; HR: 66.5 ± 23.54 versus 51.4 ± 19.34 , $P < 0.05$) (Fig. 2).


4.4. Evaluation of apoptosis after 48 h of incubation with NAC ± ATRA

ATRA alone did not modify the percentage of apoptosis in either the normals or MDS samples, but incubation with NAC + ATRA led to a significant decrease in the apoptotic rate in both the normal (2.36 ± 0.61 versus 3.74 ± 0.97 , $P < 0.05$) and MDS samples (2.06 ± 0.44 versus 3.78 ± 0.7 , $P < 0.01$). The same was observed in both the LR ($P < 0.05$) and HR ($P = 0.06$) subgroups (LR: 1.62 ± 0.34 versus 3.3 ± 0.69 ; HR: 2.71 ± 0.96 versus 4.36 ± 1.23) (Fig. 3). Apoptosis was also less in the 12 MDS samples evaluated after 48 h NAC stimulation than in controls (1.52 ± 0.85 versus 3.16 ± 1.08 , $P < 0.05$) (Fig. 3a).

4.5. Clonogenic assay (CFU-GM) after 48 h of incubation with NAC ± ATRA

Both ATRA and NAC + ATRA significantly increased clonogenic activity in both the normal ($P < 0.05$) and MDS samples ($P < 0.01$) (normal: CTRL 172.2 ± 36.06 , ATRA 329.8 ± 62.56 , NAC + ATRA 361 ± 65.29 ; MDS: CTRL 59.67 ± 15.28 , ATRA 74.76 ± 14.95 , NAC + ATRA 87.59 ± 19.56).

However although incubation with ATRA alone increased clonogenic activity in both MDS subgroups, this was statistically significant only in the LR patients ($P < 0.01$); the increase after incubation with NAC + ATRA was statistically significant in both the LR ($P < 0.01$) and HR patients ($P < 0.05$) (mean values LR: CTRL 78.58 ± 21.83 , ATRA 100.67 ± 21.64 , NAC + ATRA 110.08 ± 29.06 ; HR: CTRL 34.44 ± 18.7 , ATRA 40.22 ± 13.59 , NAC + ATRA $55.11 \pm$






Fig. 2. Effect of NAC on clonogenic activity (CFU-GM) after 24 h of liquid culture. * $P < 0.05$, ** $P < 0.01$ versus controls.

20.09) (Fig. 4). The NAC + ATRA combination conferred a significant ($P < 0.05$) advantage in terms of clonogenic potentials with respect to ATRA in the MDS samples as a whole.

After 48 h incubation with NAC alone, the increase in the clonogenic activity of the MDS samples was statistically significant (61.5 ± 12.63 versus 42.75 ± 10.48 , $P < 0.05$) in comparison with the control samples, but significantly ($P < 0.05$) less than that observed after incubation with NAC + ATRA (69 ± 13.61) (Fig. 4a).

Analysis of the colony/cluster ratio after 24 and 48 h always revealed a moderate and non-significant increase in the MDS samples as a whole (24 h: CTRL 29.42 ± 11.48 , NAC 35.99 ± 12.92 ; 48 h: CTRL 24.86 ± 8.38 , ATRA 37.35 ± 12.89 , NAC 32.83 ± 16.33 , NAC + ATRA 37.27 ± 10.91) as well as in the LR (24 h: CTRL 45.93 ± 20.41 , NAC 56.06 ± 20.46 ; 48 h: CTRL 37.13 ± 13.84 , ATRA 54.98 ± 21.04 , NAC 52.03 ± 29.12 , NAC + ATRA 49.49 ± 16.17) and HR patients (24 h: CTRL 11.08 ± 4.98 , NAC 13.69 ± 6.66 ; 48 h: CTRL 11.05 ± 6.55 , ATRA 17.52 ± 11.46 , NAC 13.63 ± 8.81 , NAC + ATRA 22 ± 13.02). We never observed a reduction in the colony/cluster ratio of any patient sample or under any culture conditions.

The data obtained using methylcellulose assay were comparable to those derived from agar assay (data not shown).

4.6. TNF- α levels in BM plasma and liquid culture

BM plasma TNF- α levels were significantly higher ($P < 0.01$) in the MDS patients (36.94 ± 3.58 , range

0.44, range 3.06–13.77 pg/ml). No difference was found between the LR and HR subgroups, although the highest TNF- α (70.81 pg/ml) value was observed in a LR patient (Fig. 5). However, the patients with TNF- α levels of > 50 pg/ml also responded to NAC in terms of CFU-GM and apoptosis.

The TNF- α levels in the supernatants of 24 h BM MDS liquid cultures showed a significant ($P < 0.05$) decrease after incubation with NAC (16.99 ± 6.22) in comparison with the control samples (26.72 ± 5.78) (Fig. 6).

5. Discussion

The apparently bizarre behaviour of MDS hemopoiesis, which is expressed in the form of peripheral cytopenia associated with normo-hypercellular bone marrow, is the consequence of increased apoptosis and the maturation arrest of MDS hemopoietic progenitors. It is also known that high levels of TNF- α (a pro-apoptotic agent) are found in the serum of MDS patients, and so the documented oxidative damage to MDS CD34+ cells could also be the result of TNF- α induced free radical production.

On the basis of these observations, we evaluated the effect of an antioxidant (and anti-apoptotic) agent (NAC) and a differentiating agent (ATRA), alone and in association, on clonogenic activity and apoptosis in MDS BM mononuclear cells.



Our study showed the in vitro ability of NAC to enhance hemopoiesis in MDS, even in the presence of a large percentage of blasts. After 24 and 48 h of incubation with NAC,

of CFU-GM in the MDS samples as a whole, as well as in the LR and HR groups. A consensual decrease in the apoptotic rate was seen after 24 and 48 h NAC stimulation. These data indirectly suggest that apoptosis plays a role even in the MDS HR subset. Moreover, ATRA did not have any adverse effects on erythroid colonies, evaluated in methylcellulose assay (data not shown). NAC alone, in fact, slightly enhanced the number of BFU-E colonies whereas the association ATRA-NAC neither increased nor decreased the number of colonies.

As a result of the physiological senescence of cultured cells, the apoptosis evaluated in the control samples (i.e. after incubation with medium alone) was higher than that observed in the fresh samples. Moreover, the level of apoptosis was particularly high in the MDS HR subgroup. Since our observations are derived

from a mixed population of all BMMNCs, we cannot be sure whether or not this phenomenon is due to CD34+ cells. However this singular behaviour may be explained by the poor self-renewal of MDS blasts, which are less capable of proliferation than leukemic blasts, as has previously been pointed out by Aul et al. [31]. A propensity towards apoptosis therefore seems to coexist with enhanced proliferation in HR MDS cells, and this may be responsible for the relative indolence of RAEB and RAEB-t.

The efficacy of NAC may be due to an increase in intracellular glutathione (GSH) levels in MDS CD34+ cells, which in turn provides protection against the apoptosis induced by free radicals. Furthermore, NAC may also prevent the release of TNF- α from the lymphocytes still present in BM liquid cultures, a hypothesis that is apparently supported by the decreased



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.